189 related articles for article (PubMed ID: 28411401)
1. Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.
Gao Z; Cai L; Lu J; Wang C; Li Q; Chen J; Song X; Chen X; Zhang L; Zheng W; Su Z
Med Sci Monit; 2017 Apr; 23():1827-1833. PubMed ID: 28411401
[TBL] [Abstract][Full Text] [Related]
2. Tumor stem-like cells isolated from MMQ cells resist to dopamine agonist treatment.
Cai L; Chen J; Lu J; Li Q; Chen X; Zhang L; Wu J; Zheng W; Wang C; Su Z
Mol Cell Endocrinol; 2021 Sep; 535():111396. PubMed ID: 34271069
[TBL] [Abstract][Full Text] [Related]
3. Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs.
Peverelli E; Mantovani G; Vitali E; Elli FM; Olgiati L; Ferrero S; Laws ER; Della Mina P; Villa A; Beck-Peccoz P; Spada A; Lania AG
J Clin Endocrinol Metab; 2012 Mar; 97(3):967-77. PubMed ID: 22259062
[TBL] [Abstract][Full Text] [Related]
4. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
5. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
Cai L; Leng ZG; Guo YH; Lin SJ; Wu ZR; Su ZP; Lu JL; Wei LF; Zhuge QC; Jin K; Wu ZB
Endocrine; 2016 Jun; 52(3):641-51. PubMed ID: 26662185
[TBL] [Abstract][Full Text] [Related]
6. The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine.
Roof AK; Jirawatnotai S; Trudeau T; Kuzyk C; Wierman ME; Kiyokawa H; Gutierrez-Hartmann A
Endocrinology; 2018 Jun; 159(6):2421-2434. PubMed ID: 29726995
[TBL] [Abstract][Full Text] [Related]
7. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
Ben-Shlomo A; Miklovsky I; Ren SG; Yong WH; Heaney AP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Feb; 88(2):858-63. PubMed ID: 12574225
[TBL] [Abstract][Full Text] [Related]
8. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
[TBL] [Abstract][Full Text] [Related]
11. The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists.
Wu Z; Zheng Y; Xie W; Li Q; Zhang Y; Ren B; Cai L; Cheng Y; Tang H; Su Z; Wu ZB
Mol Cell Endocrinol; 2020 Dec; 518():111033. PubMed ID: 32946927
[TBL] [Abstract][Full Text] [Related]
12. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
13. Nerve growth factor suppresses the transforming phenotype of human prolactinomas.
Missale C; Boroni F; Losa M; Giovanelli M; Zanellato A; Dal Toso R; Balsari A; Spano P
Proc Natl Acad Sci U S A; 1993 Sep; 90(17):7961-5. PubMed ID: 8367448
[TBL] [Abstract][Full Text] [Related]
14. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
[TBL] [Abstract][Full Text] [Related]
15. MiR-137's Tumor Suppression on Prolactinomas by Targeting MITF and Modulating Wnt Signaling Pathway.
Lei C; Jing G; Jichao W; Xiaohui L; Fang Q; Hua G; Yazhou M; Zhang Y
J Clin Endocrinol Metab; 2019 Dec; 104(12):6391-6402. PubMed ID: 31162548
[TBL] [Abstract][Full Text] [Related]
16. Retention of dopamine 2 receptor mRNA and absence of the protein in craniospinal and extracranial metastasis of a malignant prolactinoma: a case report.
Winkelmann J; Pagotto U; Theodoropoulou M; Tatsch K; Saeger W; Müller A; Arzberger T; Schaaf L; Schumann EM; Trenkwalder C; Stalla GK
Eur J Endocrinol; 2002 Jan; 146(1):81-8. PubMed ID: 11751072
[TBL] [Abstract][Full Text] [Related]
17. Correlation of alternative splicing of the D2 dopamine receptor mRNA and estrogen receptor mRNA in the prolactinomas and gonadotrope tumors.
Wu ZB; Li CZ; Zong XY; Su ZP; Zeng YJ; Zhang YZ
J Neurooncol; 2009 Aug; 94(1):135-9. PubMed ID: 19252821
[TBL] [Abstract][Full Text] [Related]
18. Expression of dopamine 2 receptor subtype mRNA in clinically nonfunctioning pituitary adenomas.
Su Z; Wang C; Wu J; Jiang X; Chen Y; Chen Y; Zheng W; Zhuge Q; Wu Z; Zeng Y
Neurol Sci; 2012 Apr; 33(2):275-9. PubMed ID: 21748460
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.
Cuny T; Mohamed A; Graillon T; Roche C; Defilles C; Germanetti AL; Couderc B; Figarella-Branger D; Enjalbert A; Barlier A; Saveanu A
Mol Cell Endocrinol; 2012 May; 355(1):106-13. PubMed ID: 22348806
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting MAPK14 showed anti-prolactinoma effect.
Ding QY; Zhang Y; Ma L; Chen YG; Wu JH; Zhang HF; Wang X
BMC Endocr Disord; 2020 Sep; 20(1):138. PubMed ID: 32894113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]